PolyPid targets SHIELD II trial completion with top-line results in Q2 2025
Source: SeekingAlpha
2025-02-12 10:44:34 ET
More on PolyPid
- PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on PolyPid
- Historical earnings data for PolyPid
- Financial information for PolyPid
Read the full article on Seeking Alpha
For further details see:
PolyPid targets SHIELD II trial completion with top-line results in Q2 2025
PolyPid Ltd.
NASDAQ: PYPD
PYPD Trading
0.25% G/L:
$4.2605 Last:
11,919 Volume:
$4.29 Open:
PYPD Latest News
March 17, 2026 08:30:00 am
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX???'s New Drug Application
February 11, 2026 07:30:00 am
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
PYPD Stock Data
$48,610,612
10,017,659
N/A
8
N/A
Biotechnology & Life Sciences
Healthcare
IL
Petach Tikva
